Gender differences in anticoagulation and antithrombotic therapy

Area of Science:

• Cardiology
• Pharmacology
• Gender Studies

Background:

• Cardiovascular disease (CVD) is a leading global cause of death and illness.
• Thromboembolic event rates are rising in women, unlike in men.
• Current antithrombotic therapies are based on clinical trials with limited representation of diverse populations, including women.

Purpose of the Study:

• To provide an overview of existing data on gender differences in anticoagulation and antithrombotic therapy.
• To highlight the impact of gender on clinical presentation, outcomes, and treatment effectiveness in cardiovascular diseases.
• To address the generalization challenges of clinical trial results to underrepresented subgroups.

Main Methods:

• Review of current clinical studies and available data on gender-related differences in antithrombotic therapy.
• Analysis of factors contributing to gender disparities in platelet biology and coagulation.
• Examination of effectiveness and adverse event rates of antithrombotic treatments across genders.

Main Results:

• Significant gender-related differences observed in the clinical presentation and outcomes of cardiovascular diseases.
• Variations in platelet biology and coagulation reactions contribute to differing rates of thromboembolic and bleeding events between genders.
• The effectiveness and safety profiles of antithrombotic therapies may differ between men and women.

Conclusions:

• Gender is a significant factor influencing cardiovascular disease, thromboembolic events, and response to antithrombotic therapies.
• Further research and tailored treatment strategies are needed to address gender-specific needs in anticoagulation and antithrombotic therapy.
• Optimizing clinical benefit requires considering gender-related differences in treatment effectiveness and adverse events.